Israeli Stocks: Make Money in Them the Easy Way

These Israeli stocks offer diversification and even some dividends.

Jan 27, 2014 at 5:17PM

Exchange-traded funds offer a convenient way to invest in sectors or niches that interest you. If you'd like to add some Israeli stocks and companies with strong links to Israel to your portfolio but don't have the time or expertise to hand-pick a few, the Market Vectors Israel ETF (NYSEMKT:ISRA) could save you a lot of trouble. Instead of trying to figure out which Israeli stocks will perform best, you can use this ETF to invest in lots of them simultaneously.

The basics
ETFs often sport lower expense ratios than their mutual-fund cousins. This ETF, focused on Israeli stocks and companies with ties to Israel, sports a relatively low expense ratio -- an annual fee -- of 0.59%. The fund is tiny, so if you're thinking of buying, beware of possibly large spreads between its bid and ask prices. Consider using a limit order if you want to buy in.

This ETF is too young to have a meaningful enough track record to assess. As with most investments, of course, we can't expect outstanding performances in every quarter or year. Investors with conviction need to wait for their holdings to deliver.

Why Israeli stocks?
It's smart to diversify your portfolio geographically, and Israeli stocks can help you do that. (You may be surprised to learn that more than a few companies you're familiar with are based in Israel.) Despite the geopolitical strife within and around the country, Israel's economy has continued to grow.

Plenty of Israeli stocks (and ones with strong ties to Israel) had strong performances over the past year. 3-D printing specialist Stratasys, Ltd. (NASDAQ:SSYS), for example, popped 39%. It's linked to Israel through its purchase of fellow 3-D printing concern Objet. Stratasys' stock took a hit earlier this month when management offered mixed near-term projections, but bulls like the company's investments in its future that will fortify its moat and they are pleased with acquisitions such as MakerBot.

OPKO Health (NYSE:OPK) jumped 37% and is tied to Israel via its purchase of Israel's Prolor Biotech. OPKO Health has bulls hopeful about its Rayaldy drug, which targets thyroid disorder, chronic kidney disease, and vitamin D deficiency. It's also developing diagnostic tests for Alzheimer's disease and several cancers and has pharmaceutical, nutraceutical, and veterinary products on the market in Europe and Latin America. Still, while its top line is growing, OPKO's bottom line is red, and it's burning cash. Gaining FDA approvals will help boost investor confidence.

Teva Pharmaceutical Industries (NYSE:TEVA), with strong ties to OPKO Health, gained 18% and yields 2.5%. Teva Pharmaceutical has some worried about the impending patent-protection expiration of its multiple sclerosis drug Copaxone (which it's trying to delay). Bulls would remind you, though, that it's still a major player in generic drugs, with more than 140 product registrations awaiting FDA approval. Teva Pharmaceuticals recently bought NuPathe and its FDA-approved patch for migraines. Its multiple sclerosis drug Laquinimod recently failed to win approval in Europe, and Teva isn't seeking approval in the U.S. at the moment due to unimpressive trial results.

Other Israeli and Israel-related stocks didn't do quite so well over the last year but could see their fortunes change in years to come. Chipmaker Mellanox Technologies, Ltd. (NASDAQ:MLNX) shed 22%, with analysts at Stifel saying in December that it expects business to pick up and reiterating a buy rating. This month, though, Barclays analysts downgraded Mellanox to underweight, while TheStreet has it as a hold, citing growing profit margins but shrinking net income. Its last few years were quite strong, as it invested heavily in cloud computing, but its stock has been rather volatile. Mellanox Technologies will release its fourth-quarter results on Jan. 29.

The big picture
If you're interested in adding some Israeli stocks to your portfolio, consider doing so via an ETF. A well-chosen ETF can grant you instant diversification across any industry or group of companies -- and make investing in and profiting from it that much easier.

The No. 1 Way to Lose Your Wealth Without Even Knowing It
You’ve fought hard to build wealth for you and your family. Yet one all-too-common pitfall could completely derail your dreams before you even know it. That's why a company The Economist hails as "an ethical oasis" has isolated five simple questions you must answer to ensure that your financial future is really secure.

Can you answer YES to all five of these eye-opening questions?
Click here to find out -- before it’s too late!

Longtime Fool contributor Selena Maranjian, whom you can follow on Twitter, owns shares of Stratasys. The Motley Fool recommends Teva Pharmaceutical Industries. It recommends and owns shares of Stratasys. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information